Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors - Competitive Landscape, Market and Pipeline Analysis 2017 - Product Image

Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors - Competitive Landscape, Market and Pipeline Analysis 2017

  • ID: 4376154
  • Drug Pipelines
  • Region: Global
  • 127 Pages
  • DelveInsight
1 of 3
Comprehensive Insights About Pipeline Drugs Across Cyclin Dependent Kinase 4/6 Inhibitors
Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors - Competitive Landscape, Market and Pipeline Analysis 2017 provides comprehensive insights about pipeline drugs across Cyclin Dependent Kinase 4/6 inhibitors. A key objective of the report is to establish the understanding for the therapeutic competitive landscape for this mechanism of action. It provides the marketed product details in this area. It also covers the pipeline drugs that fall under Cyclin Dependent Kinase 4/6 inhibitors including their comparative analysis at various stages covering Filed, Phase II, Phase I, Pre-clinical, and inactive products, therapeutics assessment by monotherapy and combination products and molecule type. The report also provides the market drivers and barriers for CDK 4/6 inhibitors.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note: Please allow up to 24 hours for delivery after payment has been made.
Note: Product cover images may vary from those shown
2 of 3
Executive Summary
Overview
Marketed Drugs
Pipeline Therapeutics
Last Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I)
Pre-clinical Stage Products
Therapeutic Assessment: Active Products
Inactive Products
Market Drivers and Barriers
Appendix

List of Tables
Table 1: Active Pipeline Coverage by Indication
Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
Table 3: Late Stage Products (Filed)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: Discontinued Products
Table 12: Dormant Products

List of Figures
Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
Figure 4: Patent Analysis
Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
Figure 6: Late Stage Products (Filed)
Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
Figure 8: Mid Stage Products (Phase II)
Figure 9: Early Stage Products (Phase I)
Figure 10: Pre-clinical Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Discontinued Products
Figure 16: Dormant Products
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll